Last edition
News about "clinical trial "
VarmX and CSL Sign Deal Worth up to USD 2.2 Billion
Under the agreement, CSL will fully fund clinical development of VMX-C001 and pay VarmX shareholders USD 117 million upfront for an exclusive option to acquire VarmX, in a transaction worth up to USD 2.2 billion
Clinical Trial | 17/09/2025 | By Dineshwori
Study Design solution evaluates a protocol's feasibility by comparing it to similar trials using Braid, Advarra's newly launched data and AI engine. Braid is powered by a uniquely rich set of digitised protocol-related documents and operational data from over 30,000 historical studies conducted by 3,500 sponsors.
Clinical Trial | 17/09/2025 | By Dineshwori
Pulnovo Wins Two IDE Approvals for PADN Trials with CMS Coverage
Following the FDA's BDD designation granted in 2021 for Group- I, II and IV, the newly-obtained IDE approvals for Pulnovo Medical’s PADN with CMS coverage will advance clinical studies targeting Groups-I and II into the IDE stage.
Clinical Trial | 13/09/2025 | By Dineshwori
NMPA Clears Zhimeng Biopharma's Drug for Phase-II Epilepsy Trial
Zhimeng Biopharma’s drug for Phase II epilepsy trial will be evaluated in a randomized, double-blind, placebo-controlled multinational study to test its efficacy, safety, and tolerability as an adjunct therapy in adults with focal epilepsy.
Clinical Trial | 13/09/2025 | By Dineshwori
Otsuka Acquires CAN10 from Cantargia
The deal transfers Cantargia’s CAN10 antibody programme to Otsuka, with Cantargia securing an upfront payment of USD 33 Million.
Clinical Trial | 12/09/2025 | By Dineshwori | 109
Sanofi Drug Earns Fast Track Status for Wet AMD in US
Sanofi is evaluating SAR402663 in a Phase 1/2 trial (NCT06660667) for neovascular AMD. The gene therapy targets abnormal blood vessel growth, reduces retinal damage, and aims to eliminate the need for frequent intravitreal injections.
Clinical Trial | 11/09/2025 | By Dineshwori
Amgen and Kyowa Kirin Report Phase-III Results for Rocatinlimab in Atopic Dermatitis
Amgen and Kyowa Kirin report top-line results from ongoing ASCEND study evaluating Rocatinlimab’s long-term safety and efficacy in adults with moderate to severe Atopic Dermatitis following prior ROCKET trials.
Clinical Trial | 09/09/2025 | By Dineshwori
Spyre Therapeutics Initiates Dosing of First Participant in Phase 1 Trial of SPY003
The SPY003 Phase 1 Trial (NCT06873724) is a double-blind, placebo-controlled single-ascending dose study in healthy volunteers.
Clinical Trial | 31/03/2025 | By Aishwarya | 219
Ractigen Therapeutics Doses First Patient in Phase I Clinical Trial for RAG-17 in SOD1-ALS
RAG-17 received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) in March 2023, followed by the FDA's clearance of its Investigational New Drug (IND) application.
Clinical Trial | 26/12/2024 | By Aishwarya | 290
Antag Therapeutics Gets FDA Clearance IND Application for AT-7687
The study will also explore AT-7687 as a monotherapy and in combination with semaglutide, a GLP-1 receptor agonist, in healthy obese individuals.
Clinical Trial | 09/10/2024 | By Aishwarya | 325
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy